Search Filters:

The items contained in the list are being used to filter the search results. Click them to remove them from the search filter.
Displaying 81 - 100 of 426
PIPS Search Results
PIP Number Active Substance Conditions / Indications Invented Name Therapeutic area Decision Type Compliance Check Sort descending Compliance outcome Date Published
MHRA-100303-PIP01-21-M01 (update)
  • DARUNAVIR
  • COBICISTAT
  • EMTRICITABINE
  • TENOFOVIR ALAFENAMIDE
  • Treatment of human immunodeficiency virus type-1 (HIV-1) infection
  • Symtuza
  • Symtuza
  • Symtuza
  • Symtuza
  • Infectious diseases
PM: decision on the application for modification of an agreed paediatric investigation plan. No 29/07/2022
MHRA-100308-PIP01-21-M01 (update)
  • AZILSARTAN MEDOXOMIL
  • Treatment of hypertension
  • Edarbi
  • Edarbi
  • Cardiovascular Diseases
PM: decision on the application for modification of an agreed paediatric investigation plan. No 29/07/2022
MHRA-100294-PIP01-21-M01 (update)
  • BENRALIZUMAB
  • Treatment of asthma
  • FASENRA
  • FASENRA
  • FASENRA
  • FASENRA
  • FASENRA
  • FASENRA PEN
  • FASENRA
  • Pneumology - Allergology
PM: decision on the application for modification of an agreed paediatric investigation plan. No 29/07/2022
MHRA-100336-PIP01-21-M01 (update)
  • soticlestat
  • Treatment of Dravet Syndrome
  • Lennox-Gastaut Syndrome
  • Neurology
PM: decision on the application for modification of an agreed paediatric investigation plan. No 29/07/2022
MHRA-100349-PIP01-21-M01 (update)
  • Rezafungin acetate
  • Treatment of invasive candidiasis
  • Rezafungin 200 mg powder for concentrate for solution for infusion
  • Infectious diseases
PM: decision on the application for modification of an agreed paediatric investigation plan. No 29/07/2022
MHRA-100428-PIP01-22-M01 (update)
  • Lenacapavir
  • Treatment of human immunodeficiency virus (HIV-1) infection
  • Infectious diseases
PM: decision on the application for modification of an agreed paediatric investigation plan. No 29/07/2022
MHRA-100494-PIP01-22-M01 (update)
  • NIVOLUMAB
  • Malignant neoplasms of lymphoid tissue
  • Malignant neoplasms of the central nervous system
  • OPDIVO
  • OPDIVO
  • Oncology
PM: decision on the application for modification of an agreed paediatric investigation plan. No 29/07/2022
MHRA-100525-PIP01-22-M01 (update)
  • TILDRAKIZUMAB
  • Treatment of psoriasis
  • Ilumetri 100 mg solution for injection in pre-filled syringe
  • Ilumetri 100 mg solution for injection in pre-filled syringe
  • ILUMYA
  • ILUMYA
  • ILUMYA
  • Ilumetri 100 mg solution for injection in pre-filled syringe
  • Ilumetri
  • Dermatology
PM: decision on the application for modification of an agreed paediatric investigation plan. No 29/07/2022
MHRA-100162-PIP01-21-M01 (update)
  • SELEXIPAG
  • Treatment of pulmonary arterial hypertension (PAH)
  • Uptravi
  • Uptravi
  • Uptravi
  • Other: Pulmonary heart disease and diseases of pulmonary circulation
PM: decision on the application for modification of an agreed paediatric investigation plan. No 27/09/2022
MHRA-100158-PIP01-21-M01 (update)
  • PEMBROLIZUMAB
  • Treatment of Hodgkin lymphoma
  • Keytruda
  • Keytruda
  • Oncology
PM: decision on the application for modification of an agreed paediatric investigation plan. No 27/09/2022
MHRA-100240-PIP01-21-M01 (update)
  • BOSUTINIB
  • Treatment of chronic myeloid leukaemia (CML)
  • Bosulif
  • Bosulif
  • Oncology
PM: decision on the application for modification of an agreed paediatric investigation plan. No 27/09/2022
MHRA-100258-PIP01-21-M01 (update)
  • Fully human IgG1 RB-1 YTE anti-RSV F monoclonal antibody (MK-1654)
  • Prevention of lower respiratory tract infection caused by respiratory syncytial virus
  • Not available yet
  • Infectious diseases
PM: decision on the application for modification of an agreed paediatric investigation plan. No 27/09/2022
MHRA-100238-PIP01-21-M01 (update)
  • AVELUMAB
  • Treatment of malignant neoplasms of the CNS, lymphoid tissue and other malignant neoplasms.
  • Bavencio
  • Bavencio
  • Bavencio
  • Bavencio
  • Bavencio
  • Oncology
PM: decision on the application for modification of an agreed paediatric investigation plan. No 27/09/2022
MHRA-100260-PIP01-21-M01 (update)
  • CEMIPLIMAB
  • Treatment of all malignant neoplasms (except haematopoietic and lymphoid tissue)
  • Libtayo
  • Libtayo
  • Oncology
PM: decision on the application for modification of an agreed paediatric investigation plan. No 27/09/2022
MHRA-100182-PIP01-21-M01 (update)
  • Avalglucosidase alfa
  • Treatment of Pompe disease
  • Endocrinology-Gynaecology-Fertility-metabolism
PM: decision on the application for modification of an agreed paediatric investigation plan. No 27/09/2022
MHRA-100233-PIP01-21-M01 (update)
  • CABOZANTINIB
  • Treatment of malignant solid tumours
  • Cabometyx
  • Cometriq
  • Cabometyx
  • Cabometyx
  • Cabometyx
  • Cabometyx
  • Cabometyx
  • Cabometyx
  • Cabometyx
  • Cabometyx
  • Cabometyx
  • Cabometyx
  • Cabometyx
  • Cabometyx
  • Aptimetyx
  • Cabometyx
  • Cabometyx
  • Cabometyx
  • Cabometyx
  • Cabometyx
  • Cabometyx
  • Cabometyx
  • Cabometyx
  • Cabometyx
  • Cabometyx
  • Cabometyx
  • Cabometyx
  • Cabometyx
  • Cometriq
  • Cabometyx
  • Cometriq
  • Cabometyx
  • Oncology
PM: decision on the application for modification of an agreed paediatric investigation plan. No 27/09/2022
MHRA-100249-PIP01-21-M01 (update)
  • BUDESONIDE
  • GLYCOPYRRONIUM BROMIDE
  • FORMOTEROL FUMARATE DIHYDRATE
  • Treatment of asthma
  • Pneumology - Allergology
PM: decision on the application for modification of an agreed paediatric investigation plan. No 27/09/2022
MHRA-100341-PIP01-21-M01 (update)
  • ISAVUCONAZONIUM SULFATE
  • Treatment of invasive aspergillosis
  • Treatment of mucormycosis
  • Cresemba
  • Cresemba
  • Cresemba
  • Infectious diseases
PM: decision on the application for modification of an agreed paediatric investigation plan. No 27/09/2022
MHRA-100328-PIP01-21-M01 (update)
  • METRELEPTIN
  • Treatment of lipodystrophy
  • Myalepta Powder for Solution for Injection
  • Myalepta
  • Myalepta
  • Endocrinology-Gynaecology-Fertility-metabolism
PM: decision on the application for modification of an agreed paediatric investigation plan. No 27/09/2022
MHRA-100370-PIP01-21-M01 (update)
  • EX VIVO EXPANDED AUTOLOGOUS HUMAN CORNEAL EPITHELIAL CELLS CONTAINING STEM CELLS
  • Treatment of limbal stem cell deficiency due to ocular burns
  • Holoclar
  • Holoclar
  • Holoclar
  • Ophthamology
PM: decision on the application for modification of an agreed paediatric investigation plan. No 27/09/2022